Doxil is the pegylated liposomal form of doxorubicin which confers a higher likelihood to cross the BBB, therefore these findings further point to the need to strategically select agents that can be paired with ibrutinib which are ABCB1 or potentially ABCC1 substrates and can impair glioma viability, migration and growth [60]. Here, ABCC1 is linked to central nervous system cancer.